PTEN

Genetic and imaging data support the idea that lower-than-usual levels of the tumor suppressor gene PTEN can drive the formation of some ovarian cancers.

The patent application was filed by Montefiore Medical Center's Sanjay Goel and John Mariadason, who discovered the association between mutations in the PIK3CA and PTEN genes and a lack of response to EGFR inhibitors.

Data presented by Myriad at AACR support the "hypothesis that PTEN status predicts outcome after radical prostatectomy, and suggest further, that PTEN may be a clinically important molecular marker for defining aggressive prostate cancer."

The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.

The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.

Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.

In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.